Vaxart, Inc. (VXRT) income statement
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 16.3%
- Net margin
- 15.9%
- Return on equity, FY2025
- 22.3%
Financial strength
- Current ratio
- 1.60
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 69.7%
Valuation
- P/E ratio
- 3.2
- Price to sales
- 0.47
- Price to book
- 1.40
- Dividend yield
- –
See a number that looks wrong?